These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
131 related articles for article (PubMed ID: 38245023)
1. WHO Essential Medicines List and methylphenidate for ADHD in children and adolescents. Storebø OJ; Ribeiro JP; Lunde C; Gluud C Lancet Psychiatry; 2024 Feb; 11(2):93. PubMed ID: 38245023 [No Abstract] [Full Text] [Related]
2. WHO Essential Medicines List and methylphenidate for ADHD in children and adolescents. Ponnou S; Timimi S; Briffault X; Batstra L; Gøtzsche PC; Gonon F Lancet Psychiatry; 2024 Feb; 11(2):92-93. PubMed ID: 38245022 [No Abstract] [Full Text] [Related]
3. WHO Essential Medicines List and methylphenidate for ADHD in children and adolescents - Authors' reply. Cortese S; Coghill D; Mattingly GW; Rohde LA; Wong ICK; Faraone SV Lancet Psychiatry; 2024 Feb; 11(2):93-95. PubMed ID: 38245024 [No Abstract] [Full Text] [Related]
4. AACAP Endorses the Inclusion of Methylphenidate in the WHO Model Lists of Essential Medicines. Cortese S; Coghill D; Mattingly GW; Rohde LA; Thom RP; Wilens TE; Wong ICK; Faraone SV J Am Acad Child Adolesc Psychiatry; 2024 Jul; 63(7):663-665. PubMed ID: 38428579 [TBL] [Abstract][Full Text] [Related]
5. ESCAP endorses the inclusion of methylphenidate in the WHO model lists of essential medicines and in the Union list of critical medicines. Cortese S; Coghill D; Fegert JM; Mattingly GW; Rohde LA; Wong ICK; Faraone SV Eur Child Adolesc Psychiatry; 2024 May; 33(5):1605-1608. PubMed ID: 38662057 [No Abstract] [Full Text] [Related]
6. The effect of methylphenidate on oppositional defiant disorder comorbid with attention deficit/hyperactivity disorder. Serra-Pinheiro MA; Mattos P; Souza I; Pastura G; Gomes F Arq Neuropsiquiatr; 2004 Jun; 62(2B):399-402. PubMed ID: 15273834 [TBL] [Abstract][Full Text] [Related]
7. Methylphenidate for Attention-Deficit/Hyperactivity Disorder in Children and Adolescents. Storebø OJ; Simonsen E; Gluud C JAMA; 2016 May; 315(18):2009-10. PubMed ID: 27163989 [TBL] [Abstract][Full Text] [Related]
8. Is the evidence base of methylphenidate for children and adolescents with attention-deficit/hyperactivity disorder flawed? Hoekstra PJ; Buitelaar JK Eur Child Adolesc Psychiatry; 2016 Apr; 25(4):339-40. PubMed ID: 27021055 [No Abstract] [Full Text] [Related]
9. What are the benefits of methylphenidate as a treatment for children and adolescents with attention-deficit/hyperactivity disorder? Gerlach M; Banaschewski T; Coghill D; Rohde LA; Romanos M Atten Defic Hyperact Disord; 2017 Mar; 9(1):1-3. PubMed ID: 28168407 [No Abstract] [Full Text] [Related]
10. [The use of methylphenidate in children with ADHD]. Lauth B Laeknabladid; 2007 Dec; 93(12):823. PubMed ID: 18057471 [No Abstract] [Full Text] [Related]
11. Responses to methylphenidate in Attention-Deficit/Hyperactivity Disorder and normal children: update 2002. Rapoport JL; Inoff-Germain G J Atten Disord; 2002; 6 Suppl 1():S57-60. PubMed ID: 12685519 [TBL] [Abstract][Full Text] [Related]
12. The Jury Is Still Out on the Benefits and Harms of Methylphenidate for Children and Adolescents With Attention-Deficit/Hyperactivity Disorder. Storebø OJ; Faltinsen E; Zwi M; Simonsen E; Gluud C Clin Pharmacol Ther; 2018 Oct; 104(4):606-609. PubMed ID: 30006934 [TBL] [Abstract][Full Text] [Related]
13. Diagnosis and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Council on Scientific Affairs, American Medical Association. Goldman LS; Genel M; Bezman RJ; Slanetz PJ JAMA; 1998 Apr; 279(14):1100-7. PubMed ID: 9546570 [TBL] [Abstract][Full Text] [Related]
14. Guidelines and algorithms for the use of methylphenidate in children with Attention-Deficit/ Hyperactivity Disorder. Greenhill L; Beyer DH; Finkleson J; Shaffer D; Biederman J; Conners CK; Gillberg C; Huss M; Jensen P; Kennedy JL; Klein R; Rapoport J; Sagvolden T; Spencer T; Swanson JM; Volkow N J Atten Disord; 2002; 6 Suppl 1():S89-100. PubMed ID: 12685523 [TBL] [Abstract][Full Text] [Related]
15. [Neuropsychiatric bases of the methylphenidate-therapy of the attention deficit/hyperactivity disorder (ADHD)]. Huber M; Kirchler E; Niederhofer H; Gruber L Fortschr Neurol Psychiatr; 2007 May; 75(5):275-84. PubMed ID: 17443438 [TBL] [Abstract][Full Text] [Related]
17. Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. Cortese S; Adamo N; Del Giovane C; Mohr-Jensen C; Hayes AJ; Carucci S; Atkinson LZ; Tessari L; Banaschewski T; Coghill D; Hollis C; Simonoff E; Zuddas A; Barbui C; Purgato M; Steinhausen HC; Shokraneh F; Xia J; Cipriani A Lancet Psychiatry; 2018 Sep; 5(9):727-738. PubMed ID: 30097390 [TBL] [Abstract][Full Text] [Related]
18. Association of methylphenidate use and traditional and cyberbullying in adolescents with ADHD. Tural Hesapcıoglu S; Kandemir G Pediatr Int; 2020 Jun; 62(6):725-735. PubMed ID: 32022957 [TBL] [Abstract][Full Text] [Related]
19. [Efficacy and safety of stimulants and non-stimulants in adults with attention deficit hyperactivity disorder (ADHD)]. Golubchik P; Sever J; Weizman A Harefuah; 2011 Oct; 150(10):788-90, 814. PubMed ID: 22111124 [TBL] [Abstract][Full Text] [Related]
20. Influence of methylphenidate on spatial attention asymmetry in adolescents with attention deficit hyperactivity disorder (ADHD): preliminary findings. Silk TJ; Newman DP; Eramudugolla R; Vance A; Bellgrove MA Neuropsychologia; 2014 Apr; 56():178-83. PubMed ID: 24486422 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]